TransMedics Group (NASDAQ:TMDX) Receives “Hold” Rating from Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of TransMedics Group (NASDAQ:TMDX) in a research report released on Monday,Benzinga reports.

A number of other brokerages also recently weighed in on TMDX. Wall Street Zen upgraded shares of TransMedics Group from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Morgan Stanley boosted their target price on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an “equal weight” rating in a report on Friday, August 1st. Oppenheimer boosted their target price on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an “outperform” rating in a report on Tuesday, June 17th. Piper Sandler restated an “overweight” rating and set a $145.00 target price (up from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Finally, Canaccord Genuity Group boosted their target price on shares of TransMedics Group from $129.00 to $142.00 and gave the stock a “buy” rating in a report on Tuesday, July 15th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, TransMedics Group currently has an average rating of “Moderate Buy” and an average price target of $123.00.

TransMedics Group Price Performance

NASDAQ TMDX opened at $114.97 on Monday. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61. TransMedics Group has a 12-month low of $55.00 and a 12-month high of $177.00. The company has a market capitalization of $3.92 billion, a PE ratio of 59.57 and a beta of 2.09. The firm’s 50 day moving average is $121.11 and its 200-day moving average is $102.00.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.44. The business had revenue of $157.37 million for the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The firm’s revenue for the quarter was up 37.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. Equities research analysts anticipate that TransMedics Group will post 1 earnings per share for the current fiscal year.

Insider Transactions at TransMedics Group

In related news, insider Anil P. Ranganath sold 686 shares of the firm’s stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the completion of the transaction, the insider owned 13,955 shares in the company, valued at $1,950,909. This trade represents a 4.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.00% of the stock is currently owned by company insiders.

Institutional Trading of TransMedics Group

Several large investors have recently modified their holdings of TMDX. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in TransMedics Group by 244.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company’s stock valued at $209,448,000 after purchasing an additional 2,209,996 shares during the period. Braidwell LP bought a new position in TransMedics Group during the 4th quarter valued at $57,493,000. Marshall Wace LLP lifted its stake in TransMedics Group by 258.7% during the 2nd quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock valued at $73,275,000 after acquiring an additional 394,340 shares in the last quarter. Mackenzie Financial Corp lifted its stake in TransMedics Group by 73.0% during the 4th quarter. Mackenzie Financial Corp now owns 828,147 shares of the company’s stock valued at $51,635,000 after acquiring an additional 349,403 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in TransMedics Group by 1,565.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company’s stock valued at $16,820,000 after acquiring an additional 253,624 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.